Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
American Society of Clinical Oncology (ASCO)
Online
2022-02-18
DOI
10.1200/jco.21.02767
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research
- (2021) C. Belli et al. ANNALS OF ONCOLOGY
- Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial
- (2021) David A. Reardon et al. CANCER
- Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors
- (2021) James M. Cleary et al. CLINICAL CANCER RESEARCH
- Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- (2021) Al B. Benson et al. Journal of the National Comprehensive Cancer Network
- RET FISH analysis is a sensitive but highly unspecific screening method for RET fusions in lung cancer
- (2021) Teodora Radonic et al. Journal of Thoracic Oncology
- Structural variant detection in cancer genomes: computational challenges and perspectives for precision oncology
- (2021) Ianthe A. E. M. van Belzen et al. npj Precision Oncology
- Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer
- (2021) Argun Akcakanat et al. CLINICAL CANCER RESEARCH
- Clinical cancer genomic profiling
- (2021) Debyani Chakravarty et al. NATURE REVIEWS GENETICS
- Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
- (2021) Tereza Vaclova et al. Nature Communications
- Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma
- (2021) Simon Strohmeier et al. Scientific Reports
- Therapeutic Implications of Germline Testing in Patients With Advanced Cancers
- (2021) Zsofia K. Stadler et al. JOURNAL OF CLINICAL ONCOLOGY
- ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
- (2021) Thomas Powles et al. NATURE
- Limited evolution of the actionable metastatic cancer genome under therapeutic pressure
- (2021) Joris van de Haar et al. NATURE MEDICINE
- Acquired Resistance to KRASG12C Inhibition in Cancer
- (2021) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS
- (2021) A. Rose Brannon et al. Nature Communications
- Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?—Reply
- (2021) Erin F. Cobain et al. JAMA Oncology
- Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature
- (2021) K. Hodroj et al. ESMO Open
- Proficiency Testing of Standardized Samples Shows High Interlaboratory Agreement for Clinical Next Generation Sequencing–Based Hematologic Malignancy Assays With Survey Material–Specific Differences in Variant Frequencies
- (2020) Alissa Keegan et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers
- (2020) Aparna R. Parikh et al. CLINICAL CANCER RESEARCH
- RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
- (2020) Benjamin J. Solomon et al. Journal of Thoracic Oncology
- Pan-cancer analysis of whole genomes
- (2020) NATURE
- Relationship between MLH1, PMS2, MSH2, and MSH6 gene specific alterations and tumor mutational burden (TMB) in 1,057 microsatellite instability‐high solid tumors
- (2020) Mohamed E. Salem et al. INTERNATIONAL JOURNAL OF CANCER
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer
- (2020) Alex H. Wagner et al. NATURE GENETICS
- Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
- (2020) Diana M Merino et al. Journal for ImmunoTherapy of Cancer
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- Beyond the Variants: Mutational Patterns in Next-Generation Sequencing Data for Cancer Precision Medicine
- (2020) Megan Parilla et al. Frontiers in Cell and Developmental Biology
- Cancer Disparities and Health Equity: A Policy Statement From the American Society of Clinical Oncology
- (2020) Manali I. Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers
- (2020) Dongfeng Niu et al. PATHOLOGY & ONCOLOGY RESEARCH
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer
- (2020) Milan Radovich et al. JAMA Oncology
- Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
- (2020) Keith T. Flaherty et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
- (2020) Vivek Subbiah et al. LANCET ONCOLOGY
- Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
- (2020) Tareq Al Baghdadi et al. Targeted Oncology
- Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site
- (2020) Hidetoshi Hayashi et al. JAMA Oncology
- Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer
- (2020) Stephen E. Lincoln et al. JAMA Network Open
- FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions
- (2020) Diana Bradford et al. CLINICAL CANCER RESEARCH
- Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
- (2020) Kenichi Suda et al. Translational Lung Cancer Research
- Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
- (2020) V. Subbiah et al. ANNALS OF ONCOLOGY
- Colorectal carcinomas containing hypermethylated MLH1 promoter and wild type BRAF/KRAS are enriched for targetable kinase fusions
- (2019) Emiliano Cocco et al. CANCER RESEARCH
- Clinical validation of the tempus xT next-generation targeted oncology sequencing assay
- (2019) Nike Beaubier et al. Oncotarget
- Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS
- (2019) Jing Wang et al. MODERN PATHOLOGY
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- Performance Comparison of Different Analytic Methods in Proficiency Testing for Mutations in the BRAF, EGFR, and KRAS Genes: A Study of the College of American Pathologists Molecular Oncology Committee
- (2019) Joel T. Moncur et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Hyun Cheol Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from TRK Inhibitor Therapy
- (2019) Susan J. Hsiao et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma
- (2019) Lipika Goyal et al. Cancer Discovery
- Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity
- (2019) Ibiayi Dagogo-Jack et al. CLINICAL CANCER RESEARCH
- Reporting of race in genome and exome sequencing studies of cancer: a scoping review of the literature
- (2019) Adrienne Nugent et al. GENETICS IN MEDICINE
- NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
- (2019) James P. Solomon et al. MODERN PATHOLOGY
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identifying patients with NTRK fusion cancer
- (2019) J P Solomon et al. ANNALS OF ONCOLOGY
- Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations
- (2019) Christian Menzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
- (2019) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion
- (2019) Ibiayi Dagogo-Jack et al. Journal of Thoracic Oncology
- The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
- (2019) Ryohei Katayama et al. Nature Communications
- Standard operating procedure for curation and clinical interpretation of variants in cancer
- (2019) Arpad M. Danos et al. Genome Medicine
- TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
- (2019) Ezra Y Rosen et al. CLINICAL CANCER RESEARCH
- Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer
- (2019) Seyed Pairawan et al. CLINICAL CANCER RESEARCH
- Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project
- (2019) Michèle Beau-Faller et al. LUNG CANCER
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology
- (2018) Jessica J. Tao et al. Annual Review of Medicine
- Comprehensive Characterization of Cancer Driver Genes and Mutations
- (2018) Matthew H. Bailey et al. CELL
- Oncogenic Signaling Pathways in The Cancer Genome Atlas
- (2018) Francisco Sanchez-Vega et al. CELL
- Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
- (2018) Jason D. Merker et al. JOURNAL OF CLINICAL ONCOLOGY
- Standards and Guidelines for Validating Next-Generation Sequencing Bioinformatics Pipelines
- (2018) Somak Roy et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Receptor Tyrosine Kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors
- (2018) Alexa B. Schrock et al. Journal of Thoracic Oncology
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET
- The emerging clinical relevance of genomics in cancer medicine
- (2018) Michael F. Berger et al. Nature Reviews Clinical Oncology
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Driver Fusions and Their Implications in the Development and Treatment of Human Cancers
- (2018) Qingsong Gao et al. Cell Reports
- Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients
- (2018) Ari Vanderwalde et al. Cancer Medicine
- Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing
- (2018) Annette S. Kim et al. JAMA Oncology
- A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
- (2018) J Mateo et al. ANNALS OF ONCOLOGY
- Molecular characterization of cancers with NTRK gene fusions
- (2018) Zoran Gatalica et al. MODERN PATHOLOGY
- A machine learning approach for somatic mutation discovery
- (2018) Derrick E. Wood et al. Science Translational Medicine
- Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
- (2018) Alexander Drilon et al. Cancer Discovery
- Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing–Based Oncology Assays
- (2018) Jason D. Merker et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Molecular and Computational Methods for the Detection of Microsatellite Instability in Cancer
- (2018) Laura G. Baudrin et al. Frontiers in Oncology
- Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing
- (2017) Diana Mandelker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline
- (2017) Timothy Gilligan et al. JOURNAL OF CLINICAL ONCOLOGY
- Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
- (2017) Marilyn M. Li et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR -Activating Mutation
- (2017) Juan Francisco Rodríguez-Moreno et al. Journal of the National Comprehensive Cancer Network
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
- (2017) Elizabeth R Plimack et al. LANCET ONCOLOGY
- Integrative clinical genomics of metastatic cancer
- (2017) Dan R. Robinson et al. NATURE
- Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
- (2017) Zhan Yao et al. NATURE
- CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer
- (2017) Malachi Griffith et al. NATURE GENETICS
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
- (2017) Steven Lemery et al. NEW ENGLAND JOURNAL OF MEDICINE
- Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
- (2017) Janet Woodcock et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence and detection of low-allele-fraction variants in clinical cancer samples
- (2017) Hyun-Tae Shin et al. Nature Communications
- Accelerating Discovery of Functional Mutant Alleles in Cancer
- (2017) Matthew T. Chang et al. Cancer Discovery
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors
- (2017) Alexander Drilon et al. Cancer Discovery
- An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
- (2017) Ariella B. Hanker et al. Cancer Discovery
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Health Disparities and Triple-Negative Breast Cancer in African American Women
- (2017) Lisa A. Newman et al. JAMA Surgery
- Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol
- (2016) F. Meric-Bernstam et al. ANNALS OF ONCOLOGY
- HGVS Recommendations for the Description of Sequence Variants: 2016 Update
- (2016) Johan T. den Dunnen et al. HUMAN MUTATION
- New paradigms in clonal evolution: punctuated equilibrium in cancer
- (2016) William CH Cross et al. JOURNAL OF PATHOLOGY
- The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations
- (2016) Linda Huang et al. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
- Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
- (2016) Alexa B. Schrock et al. Journal of Thoracic Oncology
- Classification and characterization of microsatellite instability across 18 cancer types
- (2016) Ronald J Hause et al. NATURE MEDICINE
- Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
- (2016) Lipika Goyal et al. Cancer Discovery
- Racial/Ethnic Disparities in Genomic Sequencing
- (2016) Daniel E. Spratt et al. JAMA Oncology
- Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
- (2015) Amanda J. Redig et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
- (2015) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
- (2015) Funda Meric-Bernstam et al. JNCI-Journal of the National Cancer Institute
- Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity
- (2015) Matthew T Chang et al. NATURE BIOTECHNOLOGY
- NCI-MATCH pairs tumor mutations with matching drugs
- (2015) Vicki Brower NATURE BIOTECHNOLOGY
- Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite
- (2015) Thomas G P Grünewald et al. NATURE GENETICS
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
- (2015) Funda Meric-Bernstam et al. JNCI-Journal of the National Cancer Institute
- Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site
- (2015) Jeffrey S. Ross et al. JAMA Oncology
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
- (2014) R. Katayama et al. CLINICAL CANCER RESEARCH
- Emergence of Constitutively Active Estrogen Receptor- Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
- (2014) R. Jeselsohn et al. CLINICAL CANCER RESEARCH
- Guidance for laboratories performing molecular pathology for cancer patients
- (2014) Ian A Cree et al. JOURNAL OF CLINICAL PATHOLOGY
- Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine
- (2014) Eliezer M Van Allen et al. NATURE MEDICINE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
- (2014) J. Zhang et al. SCIENCE
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes
- (2013) Tae-Min Kim et al. CELL
- Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
- (2013) Stacie B. Dusetzina et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- Mechanisms of resistance to therapies targeting BRCA-mutant cancers
- (2013) Christopher J Lord et al. NATURE MEDICINE
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed
- (2013) H. L. McLeod SCIENCE
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- The Impact of Race and Comorbidity on Survival in Endometrial Cancer
- (2012) S. H. Olson et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tamoxifen and CYP2D6: A Contradiction of Data
- (2012) D. L. Hertz et al. ONCOLOGIST
- Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment
- (2012) Christine M Walko et al. PHARMACOGENOMICS
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- Identification of Cancer Patients with Lynch Syndrome: Clinically Significant Discordances and Problems in Tissue-Based Mismatch Repair Testing
- (2011) A. N. Bartley et al. Cancer Prevention Research
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study
- (2011) William J. Irvin et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
- (2011) Sonya Blesser Streeter et al. Journal of Oncology Practice
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer
- (2010) Ganna Chornokur et al. PROSTATE
- Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
- (2009) E. A. Mittendorf et al. CLINICAL CANCER RESEARCH
- American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
- (2009) Neal J. Meropol et al. JOURNAL OF CLINICAL ONCOLOGY
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
- (2009) M. Olivier et al. Cold Spring Harbor Perspectives in Biology
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started